APPLICATIONS

Not all patients in a trial are the same — even when they share a diagnosis. Molecular differences that clinical criteria and demographic variables cannot capture may be the most important distinctions in your population. COMPASS analyzes the complete molecular landscape of blood samples across your patient cohort and identifies which features genuinely distinguish one group from another. The result is a molecular basis for stratification that goes deeper than any targeted assay can reach.

When some patients respond to a drug and others do not, the question is rarely whether the drug works. It is which patients it works for. COMPASS compares blood samples from responders and non-responders without requiring a prior hypothesis about which molecules to measure. What emerges is an unbiased view of the molecular differences between the patients your drug worked for and those it did not — a foundation for understanding response, redesigning enrollment, and identifying the patients most likely to benefit.

Many diseases are molecularly heterogeneous in ways that existing diagnostic criteria do not reflect. Patients classified under the same diagnosis may represent biologically distinct populations with different underlying drivers, different rates of progression, and different responses to treatment. COMPASS can reveal those distinctions from blood — identifying molecular subtype signatures that have clinical relevance even when they were not known to exist at the outset of the study.

The decisions made before a trial begins — who to enroll, how to stratify, which patients to exclude — shape everything that follows. When those decisions are made without a complete molecular picture of the patient population, the consequences show up in noisy results, diluted signals, and missed endpoints. COMPASS provides the molecular characterization needed to make those decisions with greater confidence — whether you are designing a Phase II based on Phase I samples, or refining a Phase III enrollment strategy based on what Phase II revealed.

When a program produces ambiguous results — a missed primary endpoint, a subgroup signal without a clear explanation, a Phase II that raised more questions than it answered — the path forward is rarely obvious. COMPASS can analyze blood samples from that study to identify molecular signatures that correlate with outcome or response. Whether a definable patient subgroup exists, whether a blood-based signature distinguishes those who responded from those who did not, whether the data supports a reformulated enrollment hypothesis — these questions can be explored from samples already collected.